SB391 - Employee protections; medicinal use of cannabis oil.

4 Co-Sponsors

Employee protections; medicinal use of cannabis oil. Amends the provision that prohibits an employer from discriminating against an employee for such employee's lawful use of medical cannabis oil, with certain exceptions, by specifying that such use must conform to the laws of the Commonwealth and by including the employees, other than law-enforcement officers, of the Commonwealth and other public bodies in such protections.

SJR69 - Commending Scott McGeary.

37 Co-Sponsors

SJR13 - Commemorating the 40th anniversary of the Honorable Yvonne Bond Miller's service in the Virginia G.A

34 Co-Sponsors

Commemorating the 40th anniversary of the Honorable Yvonne Bond Miller's service in the Virginia General Assembly.

SJR185 - Celebrating the life of Harris Nathan Miller.

20 Co-Sponsors

SR6 - Commending the Honorable Dr. Luke E. Torian.

39 Co-Sponsors

SB689 - Casino gaming; cruise ship gaming in the offshore waters of the Commonwealth.

2 Co-Sponsors

Exemptions to article; cruise ship gaming in the offshore waters of the Commonwealth.

SB660 - Health insurance; pharmacy benefits managers, reporting requirements, civil penalty.

3 Co-Sponsors

Health insurance; pharmacy benefits managers; reporting requirements; civil penalty. Provides that a person that violates the existing requirement to obtain a license prior to providing pharmacy benefits management services or otherwise acting as a pharmacy benefits manager may be subject to a civil penalty of $5,000 for each day on which such violation occurs. The bill adds additional requirements to existing reporting requirements for insurance carriers relating to pharmacy benefits managers. Such additional requirements include (i) the aggregate amount of a pharmacy benefits manager's retained rebates, as defined in the bill; (ii) a pharmacy benefits manager's aggregate retained rebate percentage, as defined in the bill; and (iii) the aggregate amount of administrative fees received by a pharmacy benefits manager.

SB122 - Pharmaceutical Services, Office of; establishes in Department of General Services, report.

2 Co-Sponsors

Department of General Services; Office of Pharmaceutical Services; report. Establishes in the Department of General Services an Office of Pharmaceutical Services to develop and execute a plan to consolidate state agency prescription drug purchasing and pharmacy benefit management programs to increase efficiency in prescription drug purchasing and constrain spending on prescription drugs. The bill directs the Department to provide to the Governor and the General Assembly an interim report on the development of the plan by November 1, 2024, and a final report on the plan by November 1, 2025.

SB695 - Virginia Crime Commission; surveillance technology, report.

3 Co-Sponsors

Virginia Crime Commission; surveillance technology; report. Adds to the powers and duties of the Virginia Crime Commission (the Commission) the power to conduct an annual study on surveillance technology, defined in the bill, utilized by local and state law-enforcement agencies throughout the Commonwealth, including (i) the technology's potential impact on privacy rights and civil liberties, with particular attention to potential disparate impacts on different communities and populations; (ii) the technology's effectiveness for law or regulatory enforcement purposes, and the likelihood that evidence collected through such technology will be considered inadmissible in a court of competent jurisdiction; (iii) the potential for the misuse of the technology or any data that is collected through the use of such technology and safeguards to prevent such misuse; (iv) existing laws and regulations governing the technology and whether additional legislation is necessary to regulate its use; and (v) any recommendation as to whether technology utilized by a locality should be implemented throughout the Commonwealth. The bill provides that the Commission shall submit a report of its findings to the Chairmen of the House Committee for Courts of Justice, the Senate Committee on the Judiciary, and the Governor within six months of beginning the study and shall make such report available to the public on the website of the Commission.

SB274 - Prescription Drug Affordability Board; established, drug cost affordability review, report.

9 Co-Sponsors

Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. The bill requires the Board to report its findings and recommendations to the General Assembly twice annually, beginning on July 1, 2025, and December 31, 2025. Provisions of the bill shall apply to state-sponsored and state-regulated health plans and health programs and obligate such policies to limit drug payment amounts and reimbursements to an upper payment limit amount set by the Board, if applicable, following an affordability review. The bill specifies that Medicare Part D plans shall not be bound by such decisions of the Board. The bill also requires the nonprofit organization contracted by the Department of Health to provide prescription drug price transparency to provide the Board access to certain data reported by manufacturers. The bill has a delayed effective date of January 1, 2025, and is identical to